Intranasal chitosan-g-HPβCD nanoparticles of efavirenz for the CNS targeting

References

• Fact sheet. 2016 UNAIDS. Available from: http://www.unaids.org/en/resources/fact-sheet.
   Google Scholar
• Nair M, Jayant RD, Kaushik A, et al. Getting into the brain: potential of nanotechnology in the management of neuroAIDS. Adv Drug Deliv Rev. 2016;103:202–217. DOI: 10.1016/j.addr.2016.02.008.
   PubMed Web of Science ®Google Scholar
• Das K, Sarma A, Chakraborty T. Nano-ART and neuroAIDS. Drug Deliv and Transl Res. 2016;6:452–72. DOI 10.1007/s13346-016-0293.
   PubMed Web of Science ®Google Scholar
• Illum L. Transport of drugs from the nasal cavity to the central nervous system. Eur J Pharm Sci. 2000;11:1–18.
   PubMed Web of Science ®Google Scholar
• Hanson LR, Frey WH. Strategies for intranasal delivery of therapeutics for the prevention and treatment of neuroAIDS. J Neuroimmune Pharmacol. 2007;2:81–86.
   PubMed Web of Science ®Google Scholar
• Al-Ghananeem AM, Saeed H, Florence R, et al. Intranasal drug delivery of didanosine-loaded chitosan nanoparticles for brain targeting; an attractive route against infections caused by AIDS viruses. J Drug Target. 2010;18:381–388. DOI: 10.3109/10611860903483396.
   PubMed Web of Science ®Google Scholar
• Barbi M, Carvalho CF, Kiill CP, et al. Preparation and characterization of chitosan nanoparticles for zidovudine nasal delivery. J Nanosci Nanotechnol. 2015;15:865–874.
   PubMed Web of Science ®Google Scholar
• Dalpiaz A, Fogagnolo M, Ferraro L, et al. A, Nasal chitosan microparticles target a zidovudine prodrug to brain HIV sanctuaries. Antiviral Res. 2015;123:146–57. doi: http://dx.doi.org/10.1016/j.antiviral.2015.09.013.
   PubMed Web of Science ®Google Scholar
• Mahajan HS, Mahajan MS, Nerkar PP, et al. Nanoemulsion-based intranasal drug delivery system of saquinavir mesylate for brain targeting. Drug Deliv. 2014;21:148–154.
   PubMed Web of Science ®Google Scholar
• Chiappetta DA, Hocht C, Opezzo JA, et al. Intranasal administration of antiretroviral-loaded micelles for anatomical targeting to the brain in HIV. Nanomedicine (Lond). 2013; 8:223–237.
   PubMed Web of Science ®Google Scholar
• Mistry A, Stolnik S, Illum L. Nanoparticles for direct nose-to-brain delivery of drugs. Int J Pharm. 2009;379:146–157.
   PubMed Web of Science ®Google Scholar
• Marzolini C, Telent A, Decostered L, et al. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS. 2001;15:1193–1194.
   Google Scholar
• Prabaharan M, Mano JF. Chitosan derivatives bearing cyclodextrin cavities as novel adsorbent matrices. Carbohydr Polym. 2006;63:153–166.
   Web of Science ®Google Scholar
• Loftsson T, Jarho P, Másson M, et al. Cyclodextrins in drug delivery. Expert Opin Drug Deliv. 2005;2:335–351.
   PubMed Web of Science ®Google Scholar
• Prabaharan M, Mano JF. Hydroxypropyl chitosan bearing β-cyclodextrin cavities: Synthesis and slow release of its inclusion complex with a model hydrophobic drug. Macromol Biosci. 2005;5:965.
   PubMed Web of Science ®Google Scholar
• Belgamwar AV, Khan SA, Yeole PG. The Patent Office Journal, 3445/MUM/2015A. 2015.
   Google Scholar
• Aktas Y, Andrieux K, Alonso MJ, et al. Preparation and in vitro evaluation of chitosan nanoparticles containing a caspase inhibitor. Int J Pharm. 2005;298:378–383.
   PubMed Web of Science ®Google Scholar
• Khan S, Patil K, Bobade N, et al. Formulation of intranasal mucoadhesive temperature-mediated in situ gel containing ropinirole and evaluation of brain targeting efficiency in rats. J Drug Target. 2010;18:223–234.
   PubMed Web of Science ®Google Scholar
• Wadell C, Björk E, Camber O. Nasal drug delivery-evaluation of an in vitro model using porcine nasal mucosa. Eur J Pharm Sci. 1999;7:197–206.
   PubMed Web of Science ®Google Scholar
• Khan S, Gajbhiye C, Singhavi D, et al. In situ gel of metoprolol tartrate: physicochemical characterization, in-vitro diffusion and histological studies. Indian J Pharm Sci. 2012;74:564–570.
   PubMed Web of Science ®Google Scholar
• Khan SA, Patil KS, Yeole PG. Intranasal mucoadhesive buspirone formulation: in vitro characterization and nasal clearance studies. Pharmazie. 2008;63:348–351.
   PubMed Web of Science ®Google Scholar
• Dolly A, Griffiths JB. ‘Cell and tissue culture for medical research. John Wiley and Son.
   Google Scholar
• Mascha van den Berg P, Romeijin SG, Coos Verhoef J, et al. Serial cerebrospinal fluid sampling in a rat model to study drug uptake from the nasal cavity. J Neurosci Methods. 2002;116:99–107.
   PubMed Web of Science ®Google Scholar
• Zarghami A, Pandamooz SA, Naji M, Pourghasem M. Modified method for cerebrospinal fluid collection in anesthetized rat and evaluation of the efficacy. 2013;2:97–98.
   Google Scholar
• Veldkampa AI, Rolf PG, Meenhorstb PL, et al. Quantitative determination of efavirenz (DMP 266), a novel non-nucleoside reverse transcriptase inhibitor, in human plasma using isocratic reversed-phase high-performance liquid chromatography with ultraviolet detection. J. Chromatogr B. 1999;734:55–61.
   PubMedGoogle Scholar
• Yadav A, Jain DK. Formulation development and characterization of propranolol hydrochloride microballoons for gastroretentive floating drug delivery. Afr J Pharm Pharmacol. 2011;5:1801–1810.
   Google Scholar
• Chawla R, Jaiswal S, Mishra Z. Development and optimization of polymeric nanoparticles of antitubercular drugs using central composite factorial design. Expert Opin Drug Deliv. 2013;10:11.
   Google Scholar
• Yuan Z, Ye Y, Gao F, et al. Chitosan-graft-β-cyclodextrin nanoparticles as a carrier for controlled drug release. Int J Pharm. 2013;446:191–198.
   PubMed Web of Science ®Google Scholar
• Sajomsang W, Nuchuchua O, Gonil P, et al. Water-soluble β-cyclodextrin grafted with chitosan and its inclusion complex as a mucoadhesive eugenol carrier. Carbohydr Polym. 2012;89:623–31. DOI:10.1016/j.carbpol.03.060.
   PubMed Web of Science ®Google Scholar
• Smart JD. The basics and underlying mechanisms of mucoadhesion. Adv Drug Deliv Rev. 2005;57:1556–1568.
   PubMed Web of Science ®Google Scholar
• Talegaonkar S, Mishra PR. Intranasal delivery: an approach to bypass the blood brain barrier. I J Pharm. 2004;36:140–147.
   Google Scholar
• Weiss J, Rose J, Storch CH, et al. Modulation of human BCRP (ABCG2) activity by anti-HIV drugs. J Antimicrob Chemother. 2007;59:238–245.
   PubMed Web of Science ®Google Scholar
• Yilmaz A, Victoria W, Laura D, et al. Efavirenz pharmacokinetics in cerebrospinal fluid and plasma over a 24-hour dosing interval. Antimicrob Agents Chemother. 2012;56:4583–4585.
   PubMed Web of Science ®Google Scholar
• Best BM, Koopmans PP, Letendre SL, et al. Efavirenz concentrations in CSF exceed IC50 for wild-type HIV. J Antimicrob Chemother. 2010;66:354–357.
   PubMed Web of Science ®Google Scholar